메뉴 건너뛰기




Volumn 69, Issue 5, 2013, Pages 1113-1120

Influence of ORM1 polymorphisms on the maintenance stable warfarin dosage

Author keywords

CYP2C9; ORM1; Polymorphism; VKORC1; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN;

EID: 84879169035     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1448-6     Document Type: Article
Times cited : (13)

References (45)
  • 2
    • 49949098665 scopus 로고    scopus 로고
    • The critical path of warfarin dosing: Finding an optimal dosing strategy using pharmacogenetics
    • 18714317 10.1038/clpt.2008.133 1:CAS:528:DC%2BD1cXhtVShtr%2FL
    • Lesko LJ (2008) The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics. Clin Pharmacol Ther 84:301-303
    • (2008) Clin Pharmacol Ther , vol.84 , pp. 301-303
    • Lesko, L.J.1
  • 5
    • 66149103700 scopus 로고    scopus 로고
    • Study on binding of drug to serum protein
    • 19336995 10.1248/yakushi.129.413 1:CAS:528:DC%2BD1MXotFWrtL0%3D
    • Otagiri M (2009) Study on binding of drug to serum protein. Yakugaku Zasshi 129:413-425
    • (2009) Yakugaku Zasshi , vol.129 , pp. 413-425
    • Otagiri, M.1
  • 6
    • 0031058095 scopus 로고    scopus 로고
    • Human orosomucoid polymorphism: Molecular basis of the three common ORM1 alleles, ORM1(*)F1,ORM1(*)F2, and ORM1(*)S
    • DOI 10.1007/s004390050378
    • Yuasa I, Umetsu K, Vogt U, Nakamura H, Nanba E, Tamaki N, Irizawa Y (1997) Human orosomucoid polymorphism: molecular basis of the three common ORM1 alleles, ORM1*F1, ORM1*F2, and ORM1*S. Hum Genet 99:393-398 (Pubitemid 27095804)
    • (1997) Human Genetics , vol.99 , Issue.3 , pp. 393-398
    • Yuasa, I.1    Umetsu, K.2    Vogt, U.3    Nakamura, H.4    Nanba, E.5    Tamaki, N.6    Irizawa, Y.7
  • 7
    • 0027358933 scopus 로고
    • Genetic polymorphism of orosomucoid (ORM) in populations of the United Kingdom, Indian subcontinent, and Cambodia
    • Mastana SS, Jayasekara R, Fisher P, Sokol RJ, Papiha SS (1993) Genetic polymorphism of orosomucoid (ORM) in populations of the United Kingdom, Indian subcontinent, and Cambodia. Jpn J Hum Genet 38:289-296 (Pubitemid 23356028)
    • (1993) Japanese Journal of Human Genetics , vol.38 , Issue.3 , pp. 289-296
    • Mastana, S.S.1    Jayasekara, R.2    Fisher, P.3    Sokoi, R.J.4    Paphia, S.S.5
  • 8
    • 0032823184 scopus 로고    scopus 로고
    • Genetic polymorphisms of orosomucoid on the Han population in Nanjing of China
    • DOI 10.1016/S0009-8981(99)00157-6, PII S0009898199001576
    • Li JH, Xu JQ, Li Y, Zhuang YY, Gong JB (1999) Genetic polymorphisms of orosomucoid on the Han population in Nanjing of China. Clin Chim Acta 288:161-168 (Pubitemid 29472425)
    • (1999) Clinica Chimica Acta , vol.288 , Issue.1-2 , pp. 161-168
    • Li, J.-H.1    Xu, J.-Q.2    Li, Y.3    Zhuang, Y.-Y.4    Gong, J.-B.5
  • 9
    • 0036155217 scopus 로고    scopus 로고
    • Influence of the ORM1 phenotypes on serum unbound concentration and protein binding of quinidine
    • DOI 10.1016/S0009-8981(01)00763-X, PII S000989810100763X
    • Li JH, Xu JQ, Cao XM, Ni L, Li Y, Zhuang YY, Gong JB (2002) Influence of the ORM1 phenotypes on serum unbound concentration and protein binding of quinidine. Clin Chim Acta 317:85-92 (Pubitemid 34114022)
    • (2002) Clinica Chimica Acta , vol.317 , Issue.1-2 , pp. 85-92
    • Li, J.-H.1    Xu, J.-Q.2    Cao, X.-M.3    Ni, L.4    Li, Y.5    Zhuang, Y.-Y.6    Gong, J.-B.7
  • 10
    • 0021982083 scopus 로고
    • 1-acid glycoprotein
    • DOI 10.1007/BF00547045
    • Tinguely D, Baumann P, Conti M, Jonzier-Perey M, Schopf J (1985) Interindividual differences in the binding of antidepressives to plasma proteins: the role of the variants of alpha 1-acid glycoprotein. Eur J Clin Pharmacol 27:661-666 (Pubitemid 15167087)
    • (1985) European Journal of Clinical Pharmacology , vol.27 , Issue.6 , pp. 661-666
    • Tinguely, D.1    Baumann, P.2    Conti, M.3
  • 11
    • 42149139502 scopus 로고    scopus 로고
    • Influence of ORM1 polymorphism on serum concentration of free nortriptyline
    • 17944232 1:CAS:528:DC%2BD1cXht1Sjs7k%3D
    • Zhang C, Tu ZL, Wang QB, Cheng XL, Zhang PH (2007) Influence of ORM1 polymorphism on serum concentration of free nortriptyline. Yao Xue Xue Bao 42:843-848
    • (2007) Yao Xue Xue Bao , vol.42 , pp. 843-848
    • Zhang, C.1    Tu, Z.L.2    Wang, Q.B.3    Cheng, X.L.4    Zhang, P.H.5
  • 12
    • 33749240384 scopus 로고    scopus 로고
    • 1-acid glycoprotein) plasma concentration and genetic variants: Effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation
    • DOI 10.1016/j.clpt.2006.06.006, PII S0009923606002517
    • Colombo S, Buclin T, Decosterd LA, Telenti A, Furrer H, Lee BL, Biollaz J, Eap CB (2006) Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. Clin Pharmacol Ther 80:307-318 (Pubitemid 44479747)
    • (2006) Clinical Pharmacology and Therapeutics , vol.80 , Issue.4 , pp. 307-318
    • Colombo, S.1    Buclin, T.2    Decosterd, L.A.3    Telenti, A.4    Furrer, H.5    Lee, B.L.6    Biollaz, J.7    Eap, C.B.8
  • 13
    • 0020419857 scopus 로고
    • 1-acid glycoprotein
    • DOI 10.1016/0006-2952(82)90597-4
    • Urien S, Albengres E, Zini R, Tillement JP (1982) Evidence for binding of certain acidic drugs to alpha1-acid glycoprotein. Biochem Pharmacol 31:3687-3689 (Pubitemid 13244140)
    • (1982) Biochemical Pharmacology , vol.31 , Issue.22 , pp. 3687-3689
    • Urein, S.1    Albengres, E.2    Zini, R.3    Tillement, J.P.4
  • 17
    • 66649135003 scopus 로고    scopus 로고
    • Warfarin pharmacogenetics 2475
    • Shil AB, Strohm MP (2009) Warfarin pharmacogenetics. N Engl J Med 360:2474-75, 2475
    • (2009) N Engl J Med , vol.360 , pp. 2474-2475
    • Shil, A.B.1    Strohm, M.P.2
  • 18
    • 66649135003 scopus 로고    scopus 로고
    • Warfarin pharmacogenetics
    • 19494226 10.1056/NEJMc090579 1:CAS:528:DC%2BD1MXntVKqs7k%3D
    • Garcia DA, Hylek E (2009) Warfarin pharmacogenetics. N Engl J Med 360:2474-2475
    • (2009) N Engl J Med , vol.360 , pp. 2474-2475
    • Garcia, D.A.1    Hylek, E.2
  • 20
    • 66849132349 scopus 로고    scopus 로고
    • CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant
    • 19297519 10.1124/mol.109.054833 1:CAS:528:DC%2BD1MXmvVWqsb8%3D
    • McDonald MG, Rieder MJ, Nakano M, Hsia CK, Rettie AE (2009) CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol 75(6):1337-1346
    • (2009) Mol Pharmacol , vol.75 , Issue.6 , pp. 1337-1346
    • McDonald, M.G.1    Rieder, M.J.2    Nakano, M.3    Hsia, C.K.4    Rettie, A.E.5
  • 22
    • 65549085682 scopus 로고    scopus 로고
    • CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population
    • 19207028 10.2217/14622416.10.2.261 1:CAS:528:DC%2BD1MXhslSgu7o%3D
    • Borgiani P, Ciccacci C, Forte V, Sirianni E, Novelli L, Bramanti P, Novelli G (2009) CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 10(2):261-266
    • (2009) Pharmacogenomics , vol.10 , Issue.2 , pp. 261-266
    • Borgiani, P.1    Ciccacci, C.2    Forte, V.3    Sirianni, E.4    Novelli, L.5    Bramanti, P.6    Novelli, G.7
  • 25
    • 70349574149 scopus 로고    scopus 로고
    • Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy
    • 19741565 10.1097/FPC.0b013e3283311347 1:CAS:528:DC%2BD1MXhtFGlsLbO
    • Zhang JE, Jorgensen AL, Alfirevic A, Williamson PR, Toh CH, Park BK, Pirmohamed M (2009) Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. Pharmacogenet Genomics 19(10):781-789
    • (2009) Pharmacogenet Genomics , vol.19 , Issue.10 , pp. 781-789
    • Zhang, J.E.1    Jorgensen, A.L.2    Alfirevic, A.3    Williamson, P.R.4    Toh, C.H.5    Park, B.K.6    Pirmohamed, M.7
  • 26
    • 77949876162 scopus 로고    scopus 로고
    • Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort
    • 20182420 10.1038/clpt.2009.307 1:CAS:528:DC%2BC3cXjs1ajsbc%3D
    • Perini JA, Struchiner CJ, Silva-Assunção E, Suarez-Kurtz G (2010) Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort. Clin Pharmacol Ther 87(4):417-420
    • (2010) Clin Pharmacol Ther , vol.87 , Issue.4 , pp. 417-420
    • Perini, J.A.1    Struchiner, C.J.2    Silva-Assunção, E.3    Suarez-Kurtz, G.4
  • 27
    • 84861150804 scopus 로고    scopus 로고
    • Influence of CYP4F2 genotype on warfarin dose requirement - A systematic review and meta-analysis
    • 22192158 10.1016/j.thromres.2011.11.043 1:CAS:528:DC%2BC38XotVeks7k%3D
    • Liang R, Wang C, Zhao H, Huang J, Hu D, Sun Y (2012) Influence of CYP4F2 genotype on warfarin dose requirement - a systematic review and meta-analysis. Thromb Res 130(1):38-44
    • (2012) Thromb Res , vol.130 , Issue.1 , pp. 38-44
    • Liang, R.1    Wang, C.2    Zhao, H.3    Huang, J.4    Hu, D.5    Sun, Y.6
  • 29
    • 34547112822 scopus 로고    scopus 로고
    • Building individualized medicine: Prevention of adverse reactions to warfarin therapy
    • DOI 10.1124/jpet.106.117952
    • Krynetskiy E, McDonnell P (2007) Building individualized medicine: prevention of adverse reactions to warfarin therapy. J Pharmacol Exp Ther 322:427-434 (Pubitemid 47105770)
    • (2007) Journal of Pharmacology and Experimental Therapeutics , vol.322 , Issue.2 , pp. 427-434
    • Krynetskiy, E.1    McDonnell, P.2
  • 30
    • 34147162376 scopus 로고    scopus 로고
    • Pharmacogenetics of warfarin: Current status and future challenges
    • DOI 10.1038/sj.tpj.6500417, PII 6500417
    • Wadelius M, Pirmohamed M (2007) Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 7:99-111 (Pubitemid 46567142)
    • (2007) Pharmacogenomics Journal , vol.7 , Issue.2 , pp. 99-111
    • Wadelius, M.1    Pirmohamed, M.2
  • 33
    • 0015892271 scopus 로고
    • Kinetics of warfarin absorption in man
    • 4584153 1:CAS:528:DyaE2cXktVSjtr0%3D
    • Breckenridge A, Orme M (1973) Kinetics of warfarin absorption in man. Clin Pharmacol Ther 14:955-961
    • (1973) Clin Pharmacol Ther , vol.14 , pp. 955-961
    • Breckenridge, A.1    Orme, M.2
  • 34
    • 0006870774 scopus 로고
    • Warfarin. In: Evans WE, Schentag JJ, Jusko WJ (eds) Applied Therapeutics, Inc, Vancouver 31-46
    • Porter RS, Sawyer WT (1992) Warfarin. In: Evans WE, Schentag JJ, Jusko WJ (eds) Applied pharmacokinetics. Applied Therapeutics, Inc, Vancouver, pp 31-1 to 31-46
    • (1992) Applied Pharmacokinetics , pp. 31-41
    • Porter, R.S.1    Sawyer, W.T.2
  • 35
    • 0015212913 scopus 로고
    • Kinetics and clinical importance of displacement of warfarin from albumin by acidic drugs
    • 10.1111/j.1749-6632.1971.tb46901.x
    • Seller EM, Koch-Weser J (1971) Kinetics and clinical importance of displacement of warfarin from albumin by acidic drugs. Ann N Y Acad Sci 170:213-225
    • (1971) Ann N y Acad Sci , vol.170 , pp. 213-225
    • Seller, E.M.1    Koch-Weser, J.2
  • 37
    • 70349649709 scopus 로고    scopus 로고
    • A site-directed mutagenesis study of drug-binding selectivity in genetic variants of human alpha(1)-acid glycoprotein
    • 19198000 10.1002/jps.21697 1:CAS:528:DC%2BD1MXhtF2qtLjF
    • Nishi K, Ueno M, Murakami Y, Fukunaga N, Akuta T, Kadowaki D, Watanabe H, Suenaga A, Maruyama T, Otagiri M (2009) A site-directed mutagenesis study of drug-binding selectivity in genetic variants of human alpha(1)-acid glycoprotein. J Pharm Sci 98:4316-4326
    • (2009) J Pharm Sci , vol.98 , pp. 4316-4326
    • Nishi, K.1    Ueno, M.2    Murakami, Y.3    Fukunaga, N.4    Akuta, T.5    Kadowaki, D.6    Watanabe, H.7    Suenaga, A.8    Maruyama, T.9    Otagiri, M.10
  • 38
    • 0029051687 scopus 로고
    • Alpha-1-acid glycoprotein concentration and the protein binding of disopyramide in healthy subjects
    • 7657852 10.1002/j.1552-4604.1995.tb04096.x 1:CAS:528:DyaK2MXmt1Kktb4%3D
    • Kishino S, Nomura A, Di ZS, Sugawara M, Iseki K, Kakinoki S, Kitabatake A, Miyazaki K (1995) Alpha-1-acid glycoprotein concentration and the protein binding of disopyramide in healthy subjects. J Clin Pharmacol 35:510-514
    • (1995) J Clin Pharmacol , vol.35 , pp. 510-514
    • Kishino, S.1    Nomura, A.2    Di, Z.S.3    Sugawara, M.4    Iseki, K.5    Kakinoki, S.6    Kitabatake, A.7    Miyazaki, K.8
  • 39
    • 0023685931 scopus 로고
    • Binding of amitriptyline to alpha 1-acid glycoprotein and its variants
    • 2907555 10.1111/j.2042-7158.1988.tb05169.x 1:CAS:528:DyaL1MXitFM%3D
    • Eap CB, Cuendet C, Baumann P (1988) Binding of amitriptyline to alpha 1-acid glycoprotein and its variants. J Pharm Pharmacol 40:767-770
    • (1988) J Pharm Pharmacol , vol.40 , pp. 767-770
    • Eap, C.B.1    Cuendet, C.2    Baumann, P.3
  • 40
    • 84892677328 scopus 로고    scopus 로고
    • Serum A1-Acid glycoprotein concentrations in 213 healthy male subjects and relative analysis with age
    • Li J, Li Y, Gong J, Zhuang K, Yiyi K, Xu J-Q (2009) Serum A1-Acid glycoprotein concentrations in 213 healthy male subjects and relative analysis with age. Acta Universitatis Medicinalis Nanjing 20(5):336-338
    • (2009) Acta Universitatis Medicinalis Nanjing , vol.20 , Issue.5 , pp. 336-338
    • Li, J.1    Li, Y.2    Gong, J.3    Zhuang, K.4    Yiyi, K.5    Xu, J.-Q.6
  • 41
    • 80052639544 scopus 로고    scopus 로고
    • Valproic acid and warfarin: An underrecognized drug interaction
    • 21512888 10.1007/s12028-011-9544-5 1:CAS:528:DC%2BC3MXoslWitL0%3D
    • Yoon HW, Giraldo EA, Wijdicks EF (2011) Valproic acid and warfarin: an underrecognized drug interaction. Neurocrit Care 15(1):182-185
    • (2011) Neurocrit Care , vol.15 , Issue.1 , pp. 182-185
    • Yoon, H.W.1    Giraldo, E.A.2    Wijdicks, E.F.3
  • 42
    • 0028959511 scopus 로고
    • Hypothesized interaction between valproic acid and warfarin
    • 7782487 10.1097/00004714-199504000-00010 1:STN:280:DyaK2MzgtFOgtw%3D%3D
    • Guthrie SK, Stoysich AM, Bader G, Hilleman DE (1995) Hypothesized interaction between valproic acid and warfarin. J Clin Psychopharmacol 15(2):138-139
    • (1995) J Clin Psychopharmacol , vol.15 , Issue.2 , pp. 138-139
    • Guthrie, S.K.1    Stoysich, A.M.2    Bader, G.3    Hilleman, D.E.4
  • 44
    • 0032492964 scopus 로고    scopus 로고
    • Influence of indinavir and ritonavir on warfarin anticoagulant activity [7]
    • Gatti G, Alessandrini A, Camera M, Di Biagio A, Bassetti M, Rizzo F (1998) Influence of indinavir and ritonavir on warfarin anticoagulant activity. Aids 12:825-826 (Pubitemid 28190712)
    • (1998) AIDS , vol.12 , Issue.7 , pp. 825-826
    • Gatti, G.1    Alessandrini, A.2    Camera, M.3    Di Biagio, A.4    Bassetti, M.5    Rizzo, F.6
  • 45
    • 0032425376 scopus 로고    scopus 로고
    • Potential interaction involving warfarin and ritonavir
    • DOI 10.1345/aph.17456
    • Knoell KR, Young TM, Cousins ES (1998) Potential interaction involving warfarin and ritonavir. Ann Pharmacother 32:1299-1302 (Pubitemid 29013352)
    • (1998) Annals of Pharmacotherapy , vol.32 , Issue.12 , pp. 1299-1302
    • Knoell, K.R.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.